BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19395984)

  • 1. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease.
    Alexander TH; Weisman MH; Derebery JM; Espeland MA; Gantz BJ; Gulya AJ; Hammerschlag PE; Hannley M; Hughes GB; Moscicki R; Nelson RA; Niparko JK; Rauch SD; Telian SA; Brookhouser PE; Harris JP
    Otol Neurotol; 2009 Jun; 30(4):443-8. PubMed ID: 19395984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.
    Harris JP; Weisman MH; Derebery JM; Espeland MA; Gantz BJ; Gulya AJ; Hammerschlag PE; Hannley M; Hughes GB; Moscicki R; Nelson RA; Niparko JK; Rauch SD; Telian SA; Brookhouser PE
    JAMA; 2003 Oct; 290(14):1875-83. PubMed ID: 14532316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune inner ear disease.
    Ruckenstein MJ
    Curr Opin Otolaryngol Head Neck Surg; 2004 Oct; 12(5):426-30. PubMed ID: 15377956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-mediated inner ear disease: 10-year experience.
    Broughton SS; Meyerhoff WE; Cohen SB
    Semin Arthritis Rheum; 2004 Oct; 34(2):544-8. PubMed ID: 15505770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
    Jover JA; Hernández-García C; Morado IC; Vargas E; Bañares A; Fernández-Gutiérrez B
    Ann Intern Med; 2001 Jan; 134(2):106-14. PubMed ID: 11177313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive therapy for autoimmune inner ear disease.
    Buniel MC; Geelan-Hansen K; Weber PC; Tuohy VK
    Immunotherapy; 2009 May; 1(3):425-34. PubMed ID: 19885385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial.
    Rauch SD; Halpin CF; Antonelli PJ; Babu S; Carey JP; Gantz BJ; Goebel JA; Hammerschlag PE; Harris JP; Isaacson B; Lee D; Linstrom CJ; Parnes LS; Shi H; Slattery WH; Telian SA; Vrabec JT; Reda DJ
    JAMA; 2011 May; 305(20):2071-9. PubMed ID: 21610239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demystifying autoimmune inner ear disease.
    Das S; Bakshi SS; Seepana R
    Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3267-3274. PubMed ID: 31605190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments.
    Harris DA; Mikulec AA; Carls SL
    Am J Audiol; 2013 Jun; 22(1):120-4. PubMed ID: 23800807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease.
    Vambutas A; Lesser M; Mullooly V; Pathak S; Zahtz G; Rosen L; Goldofsky E
    J Clin Invest; 2014 Sep; 124(9):4115-22. PubMed ID: 25133431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease.
    Derebery MJ; Fisher LM; Voelker CC; Calzada A
    Otol Neurotol; 2014 Oct; 35(9):1515-21. PubMed ID: 25203561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial audiometry in a clinical trial of AIED treatment.
    Niparko JK; Wang NY; Rauch SD; Russell GB; Espeland MA; Pierce JJ; Bowditch S; Masuda A; Gulya AJ; Gantz BJ; Hughes GB; Brookhouser PE; Hannley MT; Telian SA; Harris JP;
    Otol Neurotol; 2005 Sep; 26(5):908-17. PubMed ID: 16151337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial.
    Bernstein IL; Bernstein DI; Dubb JW; Faiferman I; Wallin B
    J Allergy Clin Immunol; 1996 Aug; 98(2):317-24. PubMed ID: 8757209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
    Van Wijk F; Staecker H; Keithley E; Lefebvre PP
    Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
    Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD
    Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
    Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
    Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review.
    Huang KH; Lin HC; Lin CD; Wu PC
    Medicine (Baltimore); 2023 Jun; 102(23):e33889. PubMed ID: 37335659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.